BDA
3.2.2023 16:18:39 CET | Business Wire | Press release
The Bermuda Business Development Agency (BDA) is pleased to announce that Gallagher Re has joined the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sponsors of the second annual Bermuda Risk Summit.
Adam Schwebach, Executive Vice President, Gallagher Re, said, “Gallagher Re is proud to support the second Bermuda Risk Summit, an annual event that showcases the breadth and versatility of Bermuda’s globally significant risk market. This event serves as a timely opportunity to connect with industry leaders ahead of midyear renewals and we applaud the BDA for their efforts in making the Bermuda Risk Summit a success.”
David Hart, BDA CEO, said, “We are just so excited to welcome Gallagher Re as our third and final headline sponsor, along with ABIR and EY. The theme of the 2023 Bermuda Risk Summit, being held from March 6-8, 2023, at the Hamilton Princess & Beach Club is ‘Innovation, Sustainability and Collaboration. We anticipate an even stronger attendance level than last year, as this event is just placed perfectly in front of an extremely important June 1 renewal season.”
Guests should act before midnight on Monday, February 6 to secure special hotel room rates starting at $359 (plus tax). From February 7, hotel room rates will increase significantly, or may be sold out, due to limited availability. To book your room please call 1-441-295-3000 or the Global Reservations Centre on 1-800-441-1414. Alternatively, click here to reserve your room online. Please use the booking code: ‘Bermuda Risk’ to take advantage of the preferred rate.
The Bermuda Risk Summit will begin with a keynote conversation with Bermuda’s Premier and BDA CEO David Hart, while Sophie Roberts, Head of The Insurer TV will moderate a group CEO panel made up of Peter Bell, CEO, Everest Re, Stephen Catlin, CEO, Convex, Chris Schaper, CEO, AIG, and Megan Thomas, CEO, Hamilton Re.
The BDA is also pleased to announce that Bermuda Brokers, Florida Insurance Council, KPMG, Meenan P.A., MS Reinsurance and Rein4ce have come on board as supporting sponsors. Goslings will be our spirits partner.
They join diamond sponsor Hyperexponential, gold sponsor SS&C, silver sponsors AM Best and Kirkland & Ellis, WIFI sponsor Demotech, supporting sponsor Aon, and our official media partner, The Insurer.
Other sponsorship opportunities are still available. Please e-mail bermudarisk@bda.bm if you wish to participate.
Some of the speakers confirmed to date include John Huff, CEO, ABIR, who will moderate a global capacity shortfall panel with Chris Bonard, CEO, ED Broking (Bermuda) Limited, Lara Mowrey, Global Head of Distribution, Guy Carpenter, Jim Fiore, Executive Managing Director, Chief Strategy Officer, Capital Advisory, Aon, and Ben Radford, Head of Gallagher Re, Bermuda.
Susanne K Murphy, Insurance Regulatory Consultant, Meenan P.A. will moderate a market perspectives from Florida’s C-Suite panel featuring Tom Gallagher, COO, People’s Trust Insurance Company, Melissa Burt DeVriese, President, Security First Insurance, Jennifer Montero, Chief Financial Officer, Florida Citizens Property Insurance Corporation and Cecil Pearce, President, Florida Insurance Council.
Suzanne Williams Charles, Director of Policy and Regulation, ABIR will moderate a panel of international regulators featuring Chlora Lindley-Myers, President, National Association of Insurance Commissioners and Gerald Gakundi, Director, Supervision (Insurance), Bermuda Monetary Authority (BMA) and Andrew Dyer, Head of London Markets, Bank of England.
Joseph Petrelli, President, Demotech and Todd Kozikowski, President, 44North, LLC, will present their findings on Florida’s disparate litigation levels.
Curtis Dickinson, Executive Adviser, Bermuda International Long-Term Insurers and Reinsurers (BILTIR) will moderate an updates from the life sector panel featuring Mark Yu, Head of Enterprise Capital Strategy, New England Asset Management, James Claxton, Associate Partner, EY, Martin Maringi, Deputy Director, Supervision (Insurance), BMA and Michelle Moloney, EVP Chief Risk Officer, Pacific Life Reinsurance.
Christian Dunleavy, Group Chief Underwriting Officer, Aspen, Chris Hayward, Chief Underwriting Officer, MS Amlin Reinsurance, Seamus Fearnon-EVP, CRT & European Markets, Arch Capital Group Ltd and Kostya Zolotusky, CEO, Itasca Re will explore the growing significance of specialty lines.
Kerr Kennedy, Associate Partner, EY, will moderate the future of cyber reinsurance panel with Yosha Delong, Global Head of Cyber, Mosaic Insurance, Noel Pearman, SVP, Cyber Product Line Leader, AXA XL, Sebastien Plummer, Cyber Specialist Broker, Gallagher Re, and Edouard Von Heberstein, CEO Spectra.
Edward Mishambi, SVP and Chief Risk Officer-Europe, Renaissance Re who will moderate a panel entitled global financing conditions – a rating agency discussion that features Peter Giacone, Global Head of Insurance, KBRA, Stefan Holzberger, Chief Rating Officer, AM Best, Brian Schneider, Senior Director, Global Analytical Co-Head, Fitch, and Joseph Petrelli.
A panel discussing investor’s experiences of Bermuda featuring Scott Frederick, Managing Partner, Sands Capital Ventures, Adrian Jones, Managing Director, Re/Insurance and Partner, HSCM Ventures, and Armin Rothauser, Senior Partner, Castlelake Investments will be moderated by Stephen Weinstein, past BDA Chair.
Saadia Savory, Vice President, Excess Casualty, Aspen, and Shannon Totten, SVP, Casualty Insurance Practice Leader Bermuda, Sompo International, will discuss Bermuda’s vibrant casualty lines of business.
And finally, Gero Michel, Group CRO, AIG Re will discuss the future of risk with Tom Johansmeyer, SVP, Head of PCS, Verisk, Susan Pateras, Deputy Chair, BDA, and Andrew Smith-Chief Risk & Sustainability Officer, Conduit Re.
The full agenda is available here.
The immediate economic impact of our 2022 event, which had a total of 350 delegates (80 from overseas), including lodging, transportation, food and beverage, retail and recreation was estimated at over one million dollars, and supported around 200 jobs.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230203005294/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom